BioSpace News Archive

Biotech Bay

Bio-Rad Introduces EveryBlot Blocking Buffer that Offers 5-Minute Blocking Time and Greater Sensitivity for Western Blots

EveryBlot Blocking Buffer provides 5-minute blocking and maximum sensitivity for western blots, regardless of the detection method.

November 17, 2019
·
3 min read
Business

MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

MorphoSys announced the opening of its new U.S. headoffice. Based in Boston, MA, one of the world’s leading innovation and biotech hubs, the new location will enable MorphoSys to establish and expand its U.S.

November 17, 2019
·
4 min read
Drug Development

Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial

Data were consistent in patients with and without type 2 diabetes, showed early effects in the first month and improvement in patient-reported outcomes

November 17, 2019
·
10 min read
Pharm Country

Teens with Heart Disease Improve Exercise Capacity in Large Clinical Trial

CHOP cardiologists report milestone results for Fontan survivors in multicenter, phase 3 FUEL Trial

November 17, 2019
·
4 min read
Biotech Bay

Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference

Personalis, Inc. announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18th and 19th.

November 17, 2019
·
2 min read
Business

Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

This analysis on effectiveness also shows Jardiance® (empagliflozin) was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists

November 17, 2019
·
16 min read
Drug Development

Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

Karuna Therapeutics, Inc. announced it will hold a webcast and conference call on Monday, November 18, 2019 at 8:30 a.m. EST to provide results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.

November 17, 2019
·
1 min read
BioMidwest

Mezzion Pharma announces the presentation of the FUEL Trial data at the American Heart Association Meeting in Philadelphia

Mezzion Pharma Co. Ltd. announces the presentation of data from its pivotal clinical trial for its new orphan drug for the treatment of adolescents with single ventricle heart disease.

November 17, 2019
·
10 min read
Business

3SBio Selects Verseau’s PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

PSGL-1, a novel target for immunotherapy, can induce macrophage reprogramming and activate a coordinated anti-tumor inflammatory response

November 17, 2019
·
6 min read
Business

AVITA Medical Names David McIntyre as Chief Financial Officer

Appointment Enhances Executive Leadership Team as AVITA Medical Broadens Access to Investors and Continues Growth Trajectory

November 17, 2019
·
6 min read